Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis.

CONTEXT Depression and substance abuse are common and costly disorders that frequently co-occur, but controversy about effective treatment for patients with both disorders persists. OBJECTIVE To conduct a systematic review and meta-analysis to quantify the efficacy of antidepressant medications for treatment of combined depression and substance use disorders. DATA SOURCES PubMed, MEDLINE, and Cochrane database search (1970-2003), using the keywords antidepressant treatment or treatment depressed in conjunction with each of the following alcohol dependence, benzodiazepine dependence, opiate dependence, cocaine dependence, marijuana dependence, and methadone; a search of bibliographies; and consultation with experts in the field. STUDY SELECTION Among inclusion criteria used for study selection were prospective, parallel group, double-blind, controlled clinical trials with random assignment to an antidepressant medication or placebo for which trial patients met standard diagnostic criteria for current alcohol or other drug use and a current unipolar depressive disorder. Of the more than 300 citations extracted, 44 were placebo-controlled clinical trials, 14 of which were selected for this analysis and included 848 patients: 5 studies of tricyclic antidepressants, 7 of selective serotonin re-uptake inhibitors, and 2 from other classes DATA EXTRACTION We independently screened the titles and abstracts of each citation, identified placebo-controlled trials of patients with both substance dependence and depression, applied the inclusion criteria, and reached consensus. Data on study methods, sample characteristics, and depression and substance use outcomes were extracted. The principal measure of effect size was the standardized difference between means on the Hamilton Depression Scale (HDS). DATA SYNTHESIS For the HDS score, the pooled effect size from the random-effects model was 0.38 (95% confidence interval, 0.18-0.58). Heterogeneity of effect on HDS across studies was significant (P <.02), and studies with low placebo response showed larger effects. Moderator analysis suggested that diagnostic methods and concurrent psychosocial interventions influenced outcome. Studies with larger depression effect sizes (>0.5) demonstrated favorable effects of medication on measures of quantity of substance use, but rates of sustained abstinence were low. CONCLUSIONS Antidepressant medication exerts a modest beneficial effect for patients with combined depressive- and substance-use disorders. It is not a stand-alone treatment, and concurrent therapy directly targeting the addiction is also indicated. More research is needed to understand variations in the strength of the effect, but the data suggest that care be exercised in the diagnosis of depression-either by observing depression to persist during at least a brief period of abstinence or through efforts by clinical history to screen out substance-related depressive symptoms.

[1]  M. Thase,et al.  Double-blind fluoxetine in depressed alcoholic smokers. , 1997, Psychopharmacology bulletin.

[2]  J. Russo,et al.  Nefazodone treatment of major depression in alcohol-dependent patients: a double-blind, placebo-controlled trial. , 2000, Journal of clinical psychopharmacology.

[3]  J. Wilkins,et al.  A multicenter trial of bupropion for cocaine dependence in methadone-maintained patients. , 1995, Drug and alcohol dependence.

[4]  A. Cnaan,et al.  Double-Blind Clinical Trial of Sertraline Treatment for Alcohol Dependence , 2001, Journal of clinical psychopharmacology.

[5]  R. Baldessarini,et al.  Suicide attempts in major affective disorder patients with comorbid substance use disorders. , 1999, The Journal of clinical psychiatry.

[6]  R. Anton,et al.  Sertraline and Cognitive Behavioral Therapy for Depressed Alcoholics: Results of A Placebo-Controlled Trial , 2003, Journal of clinical psychopharmacology.

[7]  I. Wilson,et al.  Tofranil in the treatment of post alcoholic depressions. , 1970, Psychosomatics.

[8]  J. Mann,et al.  Preliminary report: double-blind, placebo-controlled study of fluoxetine in depressed alcoholics. , 1995, Psychopharmacology bulletin.

[9]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[10]  P. McGrath,et al.  Imipramine treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trial. , 1998, Archives of general psychiatry.

[11]  C. Sherbourne,et al.  The quality of care for depressive and anxiety disorders in the United States. , 2001, Archives of general psychiatry.

[12]  Stephen Rollnick,et al.  Motivational Interviewing: Preparing People for Change, 2nd Edition , 2002 .

[13]  A. Raskin,et al.  REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF‐REPORT RATINGS OF HOSPITALIZED DEPRESSIVES , 1969, The Journal of nervous and mental disease.

[14]  D. Klein,et al.  Imipramine treatment of cocaine abuse: possible boundaries of efficacy. , 1995, Drug and alcohol dependence.

[15]  R. Kessler,et al.  Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. , 1997, Archives of general psychiatry.

[16]  D. W. Goodwin,et al.  Pharmacological treatment of alcohol intoxication, withdrawal and dependence: a critical review. , 1987, Journal of studies on alcohol.

[17]  Mark W. Lipsey,et al.  Practical Meta-Analysis , 2000 .

[18]  F. D. Del Boca,et al.  Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. , 1995, The American journal of psychiatry.

[19]  B. Rounsaville,et al.  Differential Symptom Reduction in Depressed Cocaine Abusers Treated with Psychotherapy and Pharmacotherapy , 1995, The Journal of nervous and mental disease.

[20]  J. C. Levy,et al.  Suicidality, depression, and substance abuse in adolescence. , 1989, The American journal of psychiatry.

[21]  M. Thase,et al.  Fluoxetine versus placebo in depressed alcoholic cocaine abusers. , 1998, Psychopharmacology bulletin.

[22]  Olga V. Demler,et al.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). , 2003, JAMA.

[23]  W. Miller,et al.  Motivational interviewing: preparing people for change. , 2002 .

[24]  J. Bell,et al.  A randomised, controlled trial of fluoxetine in methadone maintenance patients with depressive symptoms. , 2002, Journal of affective disorders.

[25]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.

[26]  B. Rounsaville,et al.  Long-term changes in current psychiatric diagnoses of treated opiate addicts. , 1986, Comprehensive psychiatry.

[27]  M M Weissman,et al.  Imipramine as treatment for depression in addicts. , 1983, Archives of general psychiatry.

[28]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[29]  A. Brooks,et al.  The effect of sertraline and environmental context on treating depression and illicit substance use among methadone maintained opiate dependent patients: a controlled clinical trial. , 2004, Drug and alcohol dependence.

[30]  Juan Carlos Espinosa,et al.  Comprehensive Meta-Analysis , 2004 .

[31]  A. Feingold,et al.  Comorbid Major Depressive Disorder as a Prognostic Factor in Cocaine‐Abusing Buprenorphine‐Maintained Patients Treated with Desipramine and Contingency Management , 2003, The American journal of drug and alcohol abuse.

[32]  K. Barry,et al.  Brief physician advice for problem alcohol drinkers. A randomized controlled trial in community-based primary care practices. , 1997, JAMA.

[33]  A. T. Butterworth.  Depression associated with alcohol withdrawal. Imipramine therapy compared with placebo. , 1971, Quarterly journal of studies on alcohol.

[34]  M. Thase,et al.  Fluoxetine versus placebo in depressed alcoholics: a 1-year follow-up study. , 2000, Addictive behaviors.

[35]  A. Roy.  Placebo-controlled study of sertraline in depressed recently abstinent alcoholics , 1998, Biological Psychiatry.

[36]  J. Kocsis,et al.  A double-blind, placebo-controlled trial of desipramine for primary alcohol dependence stratified on the presence or absence of major depression. , 1996, JAMA.

[37]  M. Schuckit,et al.  Changes in depression among abstinent alcoholics. , 1988, Journal of studies on alcohol.

[38]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[39]  G. Badger,et al.  Achieving cocaine abstinence with a behavioral approach. , 1993, The American journal of psychiatry.

[40]  G. Woody,et al.  Depression and anxiety in heroin addicts: a placebo-controlled study of doxepin in combination with methadone. , 1975, The American journal of psychiatry.

[41]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[42]  D S Rae,et al.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. , 1990, JAMA.

[43]  McLean Pc,et al.  Mianserin in the treatment of depressive symptoms in alcoholics. A double-blind placebo controlled study using a computer delivered self-rating scale. , 1986 .

[44]  M. Barranco,et al.  Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double-blind study. , 1982, The Journal of clinical psychiatry.

[45]  E. Krupitsky,et al.  Baclofen administration for the treatment of affective disorders in alcoholic patients. , 1993, Drug and alcohol dependence.

[46]  E. Nunes,et al.  Antidepressant treatment in methadone maintenance patients. , 1995, Journal of addictive diseases.

[47]  M. Whooley,et al.  Managing depression in medical outpatients. , 2000, The New England journal of medicine.

[48]  F. Moeller,et al.  Fluoxetine treatment of cocaine-dependent patients with major depressive disorder. , 2001, Drug and alcohol dependence.

[49]  J. Robinson,et al.  Treatment of depression in alcoholics. , 1975, The American journal of psychiatry.

[50]  P. McGrath,et al.  Imipramine treatment of alcoholism with comorbid depression. , 1993, The American journal of psychiatry.

[51]  J. Kocsis,et al.  Desipramine treatment of alcoholism. , 1991, Psychopharmacology bulletin.

[52]  R. Rosenheck,et al.  The use of antidepressants in alcohol-dependent veterans. , 2003, The Journal of clinical psychiatry.

[53]  A. Altamura,et al.  Alcoholism and depression: a placebo controlled study with viloxazine. , 1990, International journal of clinical pharmacology research.

[54]  H. Kranzler,et al.  Overview of Treatment Modalities for Dual-Diagnosis Patients: Pharmacotherapy, Psychotherapy, and 12-Step Programs , 2004 .

[55]  S. Siris,et al.  Adjunctive imipramine for dysphoric schizophrenic patients with past histories op cannabis abuse , 1992, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[56]  D. Malone,et al.  Treatment of Depression in Chronic Cocaine and Phencyclidine Abuse With Desipramine , 1986, Journal of clinical pharmacology.

[57]  G. Woody,et al.  THE USE OF ANTIDEPRESSANTS WITH METHADONE IN DEPRESSED MAINTENANCE PATIENTS * , 1982, Annals of the New York Academy of Sciences.

[58]  J. Stewart,et al.  Imipramine treatment of alcoholics with primary depression: A placebo-controlled clinical trial. , 1996, Archives of general psychiatry.

[59]  Cognitive-behavioral treatment for depression in alcoholism. , 1997, Journal of consulting and clinical psychology.

[60]  C D Naylor,et al.  Incorporating variations in the quality of individual randomized trials into meta-analysis. , 1992, Journal of clinical epidemiology.

[61]  N. Knight.  Suicidality, depression, and substance abuse in adolescence: Levy JC, Deykin EY Am J Psychiatry 146:1462–1467 Nov 1989 , 1990 .

[62]  M A Schuckit,et al.  Genetic and clinical implications of alcoholism and affective disorder. , 1986, The American journal of psychiatry.

[63]  R. Herning,et al.  Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. A controlled, residential study. , 1990, Archives of general psychiatry.

[64]  R. Sysko,et al.  Placebo response in studies of major depression: variable, substantial, and growing. , 2002, JAMA.

[65]  E. Tzavellas,et al.  Impact of alcohol detoxification on anxiety and depressive symptoms. , 2002, Drug and alcohol dependence.

[66]  R. Spitzer,et al.  Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. , 1999, JAMA.

[67]  E. Robins,et al.  Multiple risk factors predict suicide in alcoholism. , 1992, Archives of general psychiatry.

[68]  D. Ciraulo,et al.  Tricyclic antidepressants in the treatment of depression associated with alcoholism. , 1981, Journal of clinical psychopharmacology.

[69]  H. Feldman.  Antidepressant drug therapy: addicts vs. nonaddicts. , 1972, Psychosomatics.

[70]  M. Thase,et al.  Fluoxetine in depressed alcoholics. A double-blind, placebo-controlled trial. , 1997, Archives of general psychiatry.

[71]  M. Thase,et al.  Fluoxetine versus placebo for the marijuana use of depressed alcoholics. , 1999, Addictive behaviors.

[72]  C. McDougle,et al.  Clinical phenomenology and neurobiology of cocaine abstinence: a prospective inpatient study. , 1991, The American journal of psychiatry.

[73]  E. Nunes,et al.  Comorbidity of Alcohol, Drug, and Psychiatric Disorders: Epidemiology , 2004 .

[74]  E. Nickel,et al.  A double-blind, placebo-controlled study of nortriptyline and bromocriptine in male alcoholics subtyped by comorbid psychiatric disorders. , 1995, Alcoholism, clinical and experimental research.

[75]  J Q Shi,et al.  A sensitivity analysis for publication bias in systematic reviews , 2001, Statistical methods in medical research.

[76]  Americal Psychiatric Press.  Diagnostic and Statistical Manual of Mental Disorders, Third Edition , 1980 .

[77]  R. J. Hayes,et al.  Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.